This rebranding marks a significant shift in corporate strategy, emphasizing Ethereum accumulation, yield-generation, and institutional appeal.

The company is also monetizing its legacy biotech intellectual property assets as part of its broader strategic realignment.

ETHZilla's transformation and activities are seen as catalysts for Ethereum’s future growth and mainstream acceptance in institutional finance, potentially shifting how digital assets are utilized globally.

ETHZilla Corporation, formerly 180 Life Sciences, rebranded on August 18, 2025, to focus on Ethereum holdings and related market activities, signaling a strategic pivot from biotechnology to digital assets.

The company will also change its stock ticker from ETHZ to ETHZW, reflecting its new focus.

ETHZilla has raised $565 million through private placements and convertible notes, including a $425 million funding round to acquire approximately 94,675 ETH at an average price of $3,902.20, with holdings valued at around $419 million.

The company employs a hybrid approach combining staking, lending, liquidity provisioning, and private agreements in partnership with Electric Capital to maximize Ethereum yield and diversify risk.

Despite market fluctuations, ETHZilla continues to pursue growth through fundraising, asset monetization, and strategic rebranding efforts.

Notably, investor Peter Thiel holds a 7.5% stake in the company, which has also completed a $156 million notes sale.

The increasing institutional adoption of Ethereum is influencing macroeconomic dynamics by providing a new asset class that enhances price stability and yield for corporate treasuries, while maintaining liquidity to mitigate risks.

ETHZilla now holds approximately 94,675 ETH, valued at about $406 million, making it the fifth-largest corporate ETH holder.

Despite a slight after-hours stock decline following Ethereum's price dip from $4,380 to $4,290, the stock had previously closed up 5.26%, with ongoing positive momentum.